Quoin Pharmaceuticals Wins FDA Fast Track Status for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals, Ltd. (Nasdaq: QNRX) said the U.S. Food and Drug Administration granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disorder, the company announced on September 23, 2026. Fast Track status is intended to accelerate development and review of drugs addressing serious conditions with unmet medical need, and makes the candidate eligible for more frequent FDA interactions and potential expedited approval pathways. The designation covers QRX003 as a topical treatment. Quoin did not disclose a timeline for its next clinical or regulatory milestone, and no financial terms were reported.